Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:CNTA NASDAQ:PTCT NASDAQ:XENE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$5.88+25.6%$4.95$4.33▼$8.69$2.21B0.422.10 million shs4.17 million shsCNTACentessa Pharmaceuticals$40.50$40.16$12.74▼$40.56$6.27B1.112.15 million shsN/APTCTPTC Therapeutics$73.82-0.9%$77.47$43.17▼$90.87$6.11B0.531.45 million shs58,341 shsXENEXenon Pharmaceuticals$62.84-0.4%$58.93$30.00▼$72.66$6.05B0.611.33 million shs26,142 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos+3.31%+2.41%-3.39%-18.34%-31.55%CNTACentessa Pharmaceuticals0.00%0.00%0.00%+2.74%+166.27%PTCTPTC Therapeutics-1.19%-4.99%-8.68%+14.49%+51.13%XENEXenon Pharmaceuticals-2.83%-4.65%+4.94%+12.60%+104.41%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$5.88+25.6%$4.95$4.33▼$8.69$2.21B0.422.10 million shs4.17 million shsCNTACentessa Pharmaceuticals$40.50$40.16$12.74▼$40.56$6.27B1.112.15 million shsN/APTCTPTC Therapeutics$73.82-0.9%$77.47$43.17▼$90.87$6.11B0.531.45 million shs58,341 shsXENEXenon Pharmaceuticals$62.84-0.4%$58.93$30.00▼$72.66$6.05B0.611.33 million shs26,142 shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos+3.31%+2.41%-3.39%-18.34%-31.55%CNTACentessa Pharmaceuticals0.00%0.00%0.00%+2.74%+166.27%PTCTPTC Therapeutics-1.19%-4.99%-8.68%+14.49%+51.13%XENEXenon Pharmaceuticals-2.83%-4.65%+4.94%+12.60%+104.41%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 1.71Reduce$8.0071.12% UpsideCNTACentessa Pharmaceuticals 2.21Hold$41.332.06% UpsidePTCTPTC Therapeutics 2.79Moderate Buy$93.8325.97% UpsideXENEXenon Pharmaceuticals 3.00Buy$77.2022.35% UpsideCurrent Analyst Ratings BreakdownLatest BHC, PTCT, XENE, and CNTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2026BHCBausch Health Cos Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/22/2026BHCBausch Health Cos Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/20/2026PTCTPTC Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$95.00 ➝ $93.007/16/2026PTCTPTC Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$124.00 ➝ $130.007/7/2026PTCTPTC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$82.00 ➝ $85.007/7/2026PTCTPTC Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/6/2026XENEXenon Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/9/2026PTCTPTC Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$75.00 ➝ $108.005/27/2026PTCTPTC Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$76.00 ➝ $85.005/27/2026XENEXenon Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$80.00 ➝ $82.005/12/2026XENEXenon Pharmaceuticals JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$77.00 ➝ $80.00(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$10.27B0.17$7.54 per share0.62$1.02 per share4.58CNTACentessa PharmaceuticalsN/AN/AN/AN/A$3.92 per shareN/APTCTPTC Therapeutics$1.73B3.57$8.67 per share8.59($2.56) per share-29.10XENEXenon Pharmaceuticals$7.50M813.32N/AN/A$7.53 per share8.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos$157M-$3.24N/A1.29N/A-11.47%-2,922.77%5.63%N/ACNTACentessa Pharmaceuticals-$197.53M-$1.79N/AN/AN/AN/A-60.37%-44.17%8/11/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A34.976.56-22.58%-362.45%-6.76%7/30/2026 (Estimated)XENEXenon Pharmaceuticals-$345.91M-$4.70N/AN/AN/AN/A-49.23%-46.42%8/10/2026 (Estimated)Latest BHC, PTCT, XENE, and CNTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2026Q2 2026CNTACentessa Pharmaceuticals-$0.40N/AN/AN/AN/AN/A8/10/2026Q2 2026XENEXenon Pharmaceuticals-$1.16N/AN/AN/A$1.67 millionN/A7/30/2026Q2 2026PTCTPTC Therapeutics$0.2363N/AN/AN/A$298.63 millionN/A7/29/2026Q2 2026BHCBausch Health Cos$0.96$1.26+$0.30$0.68$2.59 billion$2.83 billion5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/7/2026Q1 2026XENEXenon Pharmaceuticals-$1.17-$1.17N/A-$1.17$1.36 millionN/A5/5/2026Q1 2026CNTACentessa Pharmaceuticals-$0.38-$0.52-$0.14-$0.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/ACNTACentessa PharmaceuticalsN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/AXENEXenon PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos54.681.320.97CNTACentessa Pharmaceuticals0.239.539.53PTCTPTC TherapeuticsN/A2.442.36XENEXenon PharmaceuticalsN/A27.7927.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%CNTACentessa Pharmaceuticals82.01%PTCTPTC TherapeuticsN/AXENEXenon Pharmaceuticals95.45%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos20.67%CNTACentessa Pharmaceuticals4.09%PTCTPTC Therapeutics5.50%XENEXenon Pharmaceuticals2.91%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,300374.03 million296.72 millionOptionableCNTACentessa Pharmaceuticals200154.73 million148.40 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableXENEXenon Pharmaceuticals21096.67 million93.85 millionOptionableBHC, PTCT, XENE, and CNTA HeadlinesRecent News About These CompaniesStempoint Capital LP Sells 207,850 Shares of Xenon Pharmaceuticals Inc. $XENE4 hours ago | marketbeat.com26,186 Shares in Xenon Pharmaceuticals Inc. $XENE Acquired by SummitTX Capital L.P.July 30 at 5:20 AM | marketbeat.comRedmile Group LLC Purchases 128,792 Shares of Xenon Pharmaceuticals Inc. $XENEJuly 29 at 5:52 AM | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Acquired by ADAR1 Capital Management LLCJuly 29 at 3:12 AM | marketbeat.comXenon Pharmaceuticals Inc. $XENE is Rock Springs Capital Management LP's 9th Largest PositionJuly 28 at 6:56 AM | marketbeat.comEversept Partners LP Lowers Holdings in Xenon Pharmaceuticals Inc. $XENEJuly 28 at 6:31 AM | marketbeat.comXenon Pharmaceuticals Inc. $XENE Shares Purchased by Swiss National BankJuly 28 at 4:16 AM | marketbeat.com64,563 Shares in Xenon Pharmaceuticals Inc. $XENE Purchased by Castleark Management LLCJuly 28 at 3:43 AM | marketbeat.comOrbimed Advisors LLC Acquires 612,771 Shares of Xenon Pharmaceuticals Inc. $XENEJuly 27 at 6:08 AM | marketbeat.comOctagon Capital Advisors LP Purchases Shares of 490,000 Xenon Pharmaceuticals Inc. $XENEJuly 27 at 5:52 AM | marketbeat.comCommodore Capital LP Trims Position in Xenon Pharmaceuticals Inc. $XENEJuly 27 at 4:15 AM | marketbeat.comAffinity Asset Advisors LLC Buys 425,000 Shares of Xenon Pharmaceuticals Inc. $XENEJuly 25, 2026 | marketbeat.comSiren L.L.C. Has $76.67 Million Stock Holdings in Xenon Pharmaceuticals Inc. $XENEJuly 24, 2026 | marketbeat.comHsbc Holdings PLC Purchases New Position in Xenon Pharmaceuticals Inc. $XENEJuly 24, 2026 | marketbeat.comAtika Capital Management LLC Has $3.48 Million Stake in Xenon Pharmaceuticals Inc. $XENEJuly 24, 2026 | marketbeat.comKBC Group NV Raises Stock Holdings in Xenon Pharmaceuticals Inc. $XENEJuly 23, 2026 | marketbeat.comAllspring Global Investments Holdings LLC Takes $13.96 Million Position in Xenon Pharmaceuticals Inc. $XENEJuly 22, 2026 | marketbeat.comJennison Associates LLC Has $76.69 Million Stake in Xenon Pharmaceuticals Inc. $XENEJuly 20, 2026 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by AnalystsJuly 20, 2026 | americanbankingnews.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by BrokeragesJuly 20, 2026 | marketbeat.comXenon Pharmaceuticals: Azetukalner Has Shifted From Binary Science To Commercial ExecutionJuly 16, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHC, PTCT, XENE, and CNTA Company DescriptionsBausch Health Cos NYSE:BHC$5.88 +1.20 (+25.62%) As of 10:22 AM Eastern This is a fair market value price provided by Massive. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Centessa Pharmaceuticals NASDAQ:CNTACentessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.PTC Therapeutics NASDAQ:PTCT$73.82 -0.67 (-0.90%) As of 10:22 AM Eastern This is a fair market value price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Xenon Pharmaceuticals NASDAQ:XENE$62.84 -0.26 (-0.41%) As of 10:21 AM Eastern This is a fair market value price provided by Massive. Learn more.Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Earnings Setup Puts Its AI Growth Story Back on Trial Again Circle’s IBM Patent Deal Could Redraw the Stablecoin Infrastructure Race Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters UnitedHealth Just Gave Wall Street a Clearer Turnaround Signal Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
